State of the art review: coronary artery disease in patients with inflammatory bowel disease: mechanisms, prevalence, and outcomes

References

• Sanchez-Muñoz F, Dominguez-Lopez A, Yamamoto-Furusho JK. Role of cytokines in inflammatory bowel disease. World J Gastroenterol. 2008;14(27):4280–4288.
   PubMed Web of Science ®Google Scholar
• Schönnbeck U, Libby P. The CD40/CD154 receptor/ligand and dyad. Cell Mol Life Sci. 2001;58:4–43.
   PubMed Web of Science ®Google Scholar
• Libby P, Geng Y, Sukhova GK, et al. Molecular determinants of atherosclerotic plaque vulnerability. Ann N Y Acad Sci. 1997;811(1):134–145.
   PubMed Web of Science ®Google Scholar
• Gerdes N, Seijkens T, Lievens D, et al. Platelet CD40 exacerbates atherosclerosis by transcellular activation of endothelial cells and leukocytes. Arterioscler Thromb Vasc Biol. 2016;36(3):482–490.
   PubMed Web of Science ®Google Scholar
• Mach F, Schönbeck U, Sukhova GK, et al. Reduction of atherosclerosis in mice by inhibition of CD40 signalling. Nature. 1998;394(6689):200–203.
   PubMed Web of Science ®Google Scholar
• Wykrzykowska JJ, Warnholtz A, de Jaeger P, et al. Effect of clopidogrel discontinuation at 1 year after drug eluting stent placement on soluble CD40L, P-selectin and C-reactive protein levels: DECADES (Discontinuation Effect of Clopidogrel After Drug Eluting Stent): a multicenter, open-label study. J Thromb Thrombolysis. 2009;28(4):410–417.
   PubMed Web of Science ®Google Scholar
• Novo S, Basili S, Tantillo R, et al. Soluble CD40L and cardiovascular risk in asymptomatic low-grade carotid stenosis. Stroke. 2005;36(3):673–675.
   PubMed Web of Science ®Google Scholar
• Varo N, de Lemos JA, Libby P, et al. Soluble CD40L: risk prediction after acute coronary syndromes. Circulation. 2003;108(9):1049–1052.
   PubMed Web of Science ®Google Scholar
• Heeschen C, Dimmeler S, Hamm CW, et al. Soluble CD40 ligand in acute coronary syndromes. N Engl J Med. 2003;348(12):1104–1111.
   PubMed Web of Science ®Google Scholar
• Scheller J, Garbers C, Rose-John S. Interleukin-6: from basic biology to selective blockade of pro-inflammatory activities. Semin Immunol. 2014; 26:2–12.
   Google Scholar
• Hunter CA, Jones SA. IL-6 as a keystone cytokine in health and disease. Nat Immunol. 2015;16(5):448–457.
   PubMed Web of Science ®Google Scholar
• Lin B, Feng D, Wang F, et al. MiR-365 participates in coronary atherosclerosis through regulating IL-6. Eur Rev Med Pharmacol Sci. 2016;20(24):5186–5192.
   PubMed Web of Science ®Google Scholar
• Saremi A, Anderson RJ, Luo P, VADT, et al. Association between IL-6 and the extent of coronary atherosclerosis in the veterans affairs diabetes trial (VADT). Atherosclerosis. 2009;203(2):610–614.
   PubMed Web of Science ®Google Scholar
• Ritschel VN, Seljeflot I, Arnesen H, et al. Circulating levels of IL‐6 receptor and gp130 and long‐term clinical outcomes in ST‐elevation myocardial infarction. JAHA. 2016;5(6):e003014.
   Web of Science ®Google Scholar
• Hsu DC, Yi Fei M, Sophia H, et al. Plasma IL-6 levels are independently associated with atherosclerosis and mortality in HIV-infected individuals on suppressive antiretroviral therapy. AIDS. 2016;30(13):2065–2074.
   PubMed Web of Science ®Google Scholar
• Bernberg E, Ulleryd MA, Johansson ME, et al. Social disruption stress increases IL-6 levels and accelerates atherosclerosis in ApoE−/− mice. Atherosclerosis. 2012;221(2):359–365.
   PubMed Web of Science ®Google Scholar
• Yoshida M, Tomitori H, Machi Y, et al. Acrolein, IL-6 and CRP as markers of silent brain infarction. Atherosclerosis. 2009;203(2):557–562.
   PubMed Web of Science ®Google Scholar
• Zhou X, Li D, Yan W, et al. Pravastatin prevents aortic atherosclerosis via modulation of signal transduction and activation of transcription 3 (STAT3) to attenuate interleukin-6 (IL-6) action in ApoE knockout mice. Int J Mol Sci. 2008;9(11):2253–2264.
   PubMed Web of Science ®Google Scholar
• Nishida M, Moriyama T, Ishii K, et al. Effects of IL-6, adiponectin, CRP and metabolic syndrome on subclinical atherosclerosis. Clin Chim Acta. 2007;384(1–2):99–104.
   PubMed Web of Science ®Google Scholar
• Idriss HT, Naismith JH. TNFα and the TNF receptor superfamily: structure–function relationship. Microsc Res Tech. 2000;50(3):184–195.
   PubMed Web of Science ®Google Scholar
• Parameswaran N, Patial S. Tumor necrosis factor-α signaling in macrophages. Crit Rev Eukaryot Gene Expr. 2010;20(2):87–103.
   PubMed Web of Science ®Google Scholar
• Zhang H, Park Y, Wu J, et al. Role of TNF-alpha in vascular dysfunction. Clin Sci. 2009;116(3):219–230.
   PubMed Web of Science ®Google Scholar
• Picchi A, Gao X, Belmadani S, et al. Tumor necrosis factor-alpha induces endothelial dysfunction in the prediabetic metabolic syndrome. Circ Res. 2006;99(1):69–77.
   PubMed Web of Science ®Google Scholar
• HüRlimann D, Forster A, Noll G, et al. Anti-tumor necrosis factor-α treatment improves endothelial function in patients with rheumatoid arthritis. Circulation. 2002;106(17):2184–2187.
   PubMed Web of Science ®Google Scholar
• Mäki-Petäjä KM, Elkhawad M, Cheriyan J, et al. Anti-tumor necrosis factor-α therapy reduces aortic inflammation and stiffness in patients with rheumatoid arthritis. Circulation. 2012;126(21):2473–2480.
   PubMed Web of Science ®Google Scholar
• Jacobsson LT, Turesson C, Gülfe A, et al. Treatment with tumor necrosis factor blockers is associated with a lower incidence of first cardiovascular events in patients with rheumatoid arthritis. J Rheumatol. 2005;32(7):1213–1218.
   PubMed Web of Science ®Google Scholar
• Dixon W, Watson K, Lunt M, British Society for Rheumatology Biologics Register, et al. Reduction in the incidence of myocardial infarction in patients with rheumatoid arthritis who respond to anti-tumor necrosis factor alpha therapy: results from the British Society for Rheumatology Biologics Register. Arthritis Rheum. 2007;56(9):2905–2912.
   PubMed Web of Science ®Google Scholar
• Cheng D, Fei Y, Saulnier P-J, et al. Circulating TNF receptors and risk of renal disease progression, cardiovascular disease events and mortality in patients with diabetes: a systematic review and meta-analysis. Endocrine. 2020;68(1):32–43.
   PubMed Web of Science ®Google Scholar
• Ntusi NA, Francis JM, Sever E, et al. Anti-TNF modulation reduces myocardial inflammation and improves cardiovascular function in systemic rheumatic diseases. Int J Cardiol. 2018;270:253–259.
   PubMed Web of Science ®Google Scholar
• Bae E, Cha R-H, Kim YC, et al. Circulating TNF receptors predict cardiovascular disease in patients with chronic kidney disease. Medicine. 2017;96(19):e6666.
   PubMed Web of Science ®Google Scholar
• Herédi E, Végh J, Pogácsás L, et al. Subclinical cardiovascular disease and it’s improvement after long‐term TNF‐α inhibitor therapy in severe psoriatic patients. J Eur Acad Dermatol Venereol. 2016;30(9):1531–1536.
   PubMed Web of Science ®Google Scholar
• Svenungsson E, Fei G, Jensen-Urstad K, et al. TNF-α: a link between hypertriglyceridaemia and inflammation in SLE patients with cardiovascular disease. Lupus. 2003;12(6):454–461.
   PubMed Web of Science ®Google Scholar
• Aviña‐Zubieta JA, Choi HK, Sadatsafavi M, et al. Risk of cardiovascular mortality in patients with rheumatoid arthritis: a meta‐analysis of observational studies. Arthritis Rheum. 2008;59(12):1690–1697.
   PubMed Web of Science ®Google Scholar
• Roman MJ, Shanker B-A, Davis A, et al. Prevalence and correlates of accelerated atherosclerosis in systemic lupus erythematosus. N Engl J Med. 2003;349(25):2399–2406.
   PubMed Web of Science ®Google Scholar
• Dement M, Martini S, Masoon F, et al. Acute myocardial infarction in setting of recently diagnoses Crohn’s disease. Presented at the American College of Cardiology Annual Meeting.
   Google Scholar
• Osterman MT, Yang Y, Brensinger C, et al. No increased risk of myocardial infarction among patients with ulcerative colitis or Crohn's disease. Clin Gastroenterol Hepatol. 2011;9(10):875–880.
   PubMed Web of Science ®Google Scholar
• Bernstein CN, Wajda A, Blanchard JF. The incidence of arterial thromboembolic diseases in inflammatory bowel disease: a population-based study. Clin Gastroenterol Hepatol. 2008;6(1):41–45.
   PubMed Web of Science ®Google Scholar
• Rungoe C, Basit S, Ranthe MF, et al. Risk of ischaemic heart disease in patients with inflammatory bowel disease: a nationwide Danish cohort study. Gut. 2013;62(5):689–694.
   PubMed Web of Science ®Google Scholar
• Singh S, Singh H, Loftus EV Jr, et al. Risk of cerebrovascular accidents and ischemic heart disease in patients with inflammatory bowel disease: a systematic review and meta-analysis. Clin Gastroenterol Hepatol. 2014;12(3):382–393.
   PubMed Web of Science ®Google Scholar
• Aniwan S, Pardi DS, Tremaine WJ, et al. Increased risk of acute myocardial infarction and heart failure in patients with inflammatory bowel diseases. Clin Gastroenterol Hepatol. 2018;16(10):1607–1615.e1.
   PubMed Web of Science ®Google Scholar
• Panhwar MS, Mansoor E, Al-Kindi SG, et al. Risk of myocardial infarction in inflammatory bowel disease: a population-based national study. Inflamm Bowel Dis. 2019;25(6):1080–1087.
   PubMed Web of Science ®Google Scholar
• Ananthakrishnan AN, McGinley EL. Infection-related hospitalizations are associated with increased mortality in patients with inflammatory bowel diseases. J Crohns Colitis. 2013;7(2):107–112.
   PubMed Web of Science ®Google Scholar
• Ehrenpreis ED, Zhou Y. Hospital costs, length of stay and prevalence of hip and knee arthroplasty in patients with inflammatory bowel disease. WJG. 2017;23(26):4752.
   PubMed Web of Science ®Google Scholar
• Ehrenpreis ED, Zhou Y, Alexoff A, et al. Effect of the diagnosis of inflammatory bowel disease on risk-adjusted mortality in hospitalized patients with acute myocardial infarction, congestive heart failure and pneumonia. PLOS One. 2016;11(7):e0158926.
   PubMed Web of Science ®Google Scholar
• Hartman MH, Groot HE, Leach IM, et al. Translational overview of cytokine inhibition in acute myocardial infarction and chronic heart failure. Trends Cardiovasc Med. 2018;28(6):369–379.
   PubMed Web of Science ®Google Scholar
• Barnes EL, Beery RM, Schulman AR, et al. Hospitalizations for acute myocardial infarction are decreased among patients with inflammatory bowel disease using a nationwide inpatient database. Inflamm Bowel Dis. 2016;22(9):2229–2237.
   PubMed Web of Science ®Google Scholar
• Kristensen SL, Ahlehoff O, Lindhardsen J, et al. Prognosis after first-time myocardial infarction in patients with inflammatory bowel disease according to disease activity: nationwide cohort study. Circulation. 2014;7(6):857–862.
   PubMed Web of Science ®Google Scholar
• Ruisi P, Makaryus JN, Ruisi M, et al. Inflammatory bowel disease as a risk factor for premature coronary artery disease. J Clin Med Res. 2015;7(4):257–261.
   PubMedGoogle Scholar
• Barnes EL, Beery RM, Schulman AR, et al. Hospitalizations for acute myocardial infarction are decreased among patients with inflammatory bowel disease using a nationwide inpatient database. Inflamm Bowel Dis. 2016;22(9):2229–2237.
   PubMed Web of Science ®Google Scholar